liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Uptake of rheumatology biosimilars in the absence of forced switching
Karolinska Inst, Sweden.
Karolinska Inst, Sweden.
Karolinska Univ Hosp, Sweden.
Umea Univ, Sweden.
Show others and affiliations
2018 (English)In: Expert Opinion on Biological Therapy, ISSN 1471-2598, E-ISSN 1744-7682, Vol. 18, no 5, p. 499-504Article in journal (Refereed) Published
Abstract [en]

Background: To describe the uptake and system-level effects of the introduction of biosimilars in a setting without forced switching.Research design and methods: We used data from the Swedish Rheumatology Quality register from start of marketing of infliximab (Remsima (R) and Inflectra (R)) and etanercept (Benepali (R)) biosimilars until 31 December 2016. We compared users of each originator-product and its biosimilar(s) by line of treatment: bDMARD-naive patients, non-medical switchers (vs. matched patients remaining on originator), and patients switching from a previous bDMARD of another type.Results: From the start of marketing 1343 patients started an infliximab biosimilar (22 months) and 2691 started etanercept (9months). Overall, the introduction of these biosimilars resulted in an increase of the total number of ongoing infliximab and etanercept treatments (originator + biosimilar) . At the end of the study period, biosimilars accounted for 31% of all infliximab treatments and 31% of all etanercept-treated patients. For each line of therapy, we noted only small differences in patient characteristics between those starting the originator product vs. its biosimilar(s).Conclusions: Introduction of biosimilars have effects beyond replacement of the originator product, in terms of an increased rate of bDMARD initiation. Selection to non-medical switching displayed no particular disease- or patient-characteristics.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD , 2018. Vol. 18, no 5, p. 499-504
Keywords [en]
bDMARD; biosimilar; rheumatology; uptake
National Category
Immunology in the medical area
Identifiers
URN: urn:nbn:se:liu:diva-148266DOI: 10.1080/14712598.2018.1458089ISI: 000432689700002PubMedID: 29633865OAI: oai:DiVA.org:liu-148266DiVA, id: diva2:1213346
Note

Funding Agencies|Swedish Foundation for Strategic Research; Swedish Research Council; Swedish Cancer Society; Swedish Heart Lung Foundation; Karolinska Institute; Stockholm County; Forskningsradet om Halsa, Arbetsliv och Valfard [2015-00689]; Stiftelsen or Strategisk Forskning; Cancerfonden; Swedish Research Council for Health, Working Life and Welfare [2015-00689]

Available from: 2018-06-04 Created: 2018-06-04 Last updated: 2018-06-25

Open Access in DiVA

fulltext(476 kB)187 downloads
File information
File name FULLTEXT02.pdfFile size 476 kBChecksum SHA-512
252ca73d860fc830ab9655c2c4eb253e339941e0f7fd66553ba263ef0841fdb977bd7f49b056fff51e30d19ea07f72ac915351cd70aa3442a19b875a4ed00f4b
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Sjöwall, Christopher
By organisation
Division of Neuro and Inflammation ScienceFaculty of Medicine and Health SciencesDepartment of Rheumatology
In the same journal
Expert Opinion on Biological Therapy
Immunology in the medical area

Search outside of DiVA

GoogleGoogle Scholar
Total: 187 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 161 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf